AbbVie to Buy Apogee Therapeutics, Bolstering Immunology Pipeline
ABBV sits 20% above its 52-week low of $181.73.
Summary
AbbVie is acquiring Apogee Therapeutics to significantly expand its immunology portfolio. This strategic move follows a series of recent positive regulatory approvals for AbbVie's existing drugs, including Rinvoq, DECNUPAZ, VENCLYXTO, and AQUIPTA. The acquisition is a major event for Apogee Therapeutics, likely resulting in a substantial premium for its shareholders, and signals AbbVie's aggressive pursuit of growth in key therapeutic areas.
At the time of this announcement, ABBV was trading at $217.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $382.5B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.